BTIG Research Reiterates Buy Rating for Sionna Therapeutics (NASDAQ:SION)

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $58.00 target price on the stock. BTIG Research’s price target points to a potential upside of 41.67% from the stock’s current price.

Several other equities analysts have also weighed in on SION. Guggenheim increased their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wedbush began coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, Citigroup began coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued an “outperform” rating on the stock. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Sionna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Stock Down 10.9%

Shares of SION opened at $40.94 on Wednesday. Sionna Therapeutics has a 12-month low of $11.77 and a 12-month high of $48.44. The firm has a market capitalization of $1.85 billion, a PE ratio of -20.99 and a beta of 1.35. The stock’s fifty day simple moving average is $38.93 and its 200-day simple moving average is $39.48.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Analysts anticipate that Sionna Therapeutics will post -2.32 EPS for the current year.

Insider Activity

In other Sionna Therapeutics news, Director Peter A. Thompson sold 235,863 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,717,760 shares of company stock worth $77,562,902 in the last three months. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several large investors have recently modified their holdings of the business. AlphaCentric Advisors LLC increased its holdings in shares of Sionna Therapeutics by 77.1% in the first quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after acquiring an additional 2,098 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after acquiring an additional 335,942 shares in the last quarter. Candriam S.C.A. bought a new stake in shares of Sionna Therapeutics in the first quarter worth about $9,494,000. Strs Ohio bought a new stake in shares of Sionna Therapeutics in the first quarter worth about $116,000. Finally, Invesco Ltd. bought a new stake in shares of Sionna Therapeutics in the fourth quarter worth about $4,573,000.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: Multiple insider sales, including large transactions by Director Peter A. Thompson and OrbiMed Advisors, may be pressuring the stock because investors often view heavy insider selling as a caution signal, even though the trades were made under pre-arranged Rule 10b5-1 plans. Article Title
• Negative Sentiment: The company missed quarterly EPS expectations, which can reinforce concerns that Sionna is still in the early, loss-making stage of development and may need time before pipeline progress translates into stronger fundamentals. Article Title
• Neutral Sentiment: Clinical milestones remain on track, including completed enrollment for the PreciSION CF study and expected summer 2026 topline data, which supports the longer-term pipeline story but does not provide an immediate commercial catalyst. Article Title
• Neutral Sentiment: A large cash balance of roughly $289.9 million reduces near-term financing risk and is a positive backdrop for a clinical-stage biotech, but it is not enough on its own to offset the earnings miss and insider selling today. Article Title

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.